LDLorien S. Dalrymple

Lorien S. Dalrymple

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lorien S. Dalrymple has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • George A. Kaysen

    Department of Medicine, University of California Davis, Davis, CA

    6 shared publications
  • Barbara Grimes

    Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA

    5 shared publications
  • Glenn M. Chertow

    Department of Medicine, Stanford University School of Medicine, Palo Alto, CA

    5 shared publications
  • Kirsten L. Johansen

    San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA; Department of Medicine, University of California San Francisco, San Francisco, CA; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA

    5 shared publications
  • Danh V. Nguyen

    Department of Medicine, University of California Irvine, Irvine, CA

    3 shared publications
  • Mark J. Sarnak

    Due to the number of contributing authors, the affiliations are provided in the Supplemental Material

    3 shared publications

Latest Publications

  • Open Access

    Outcomes of Infection-Related Hospitalization in Medicare Beneficiaries Receiving In-Center Hemodialysis

    by Lorien S. Dalrymple, Yi Mu, Patrick S. Romano, Danh V. Nguyen, Glenn M. Chertow, Cynthia Delgado, Barbara Grimes, George A. Kaysen, Kirsten L. Johansen


  • Open Access

    Comparison of Hospitalization Rates among For-Profit and Nonprofit Dialysis Facilities

    by Lorien S. Dalrymple, Kirsten L. Johansen, Patrick S. Romano, Glenn M. Chertow, Yi Mu, Julie H. Ishida, Barbara Grimes, George A. Kaysen, Danh V. Nguyen

    Summary: Background and objectives: The vast majority of US dialysis facilities are for-profit and profit status has been associated with processes of care and outcomes in patients on dialysis. This study examined whether dialysis facility profit status was associated with the rate of hospitalization in patients starting dialysis. Design, setting, participants, & methods: This was a retrospective cohort study of Medicare beneficiaries starting dialysis between 2005 and 2008 using data from the US Renal Data System. All-cause hospitalization was examined and compared between for-profit and nonprofit dialysis facilities through 2009 using Poisson regression. Companion analyses of cause-specific hospitalization that are likely to be influenced by dialysis facility practices including hospitalizations for heart failure and volume overload, access complications, or hyperkalemia were conducted. Results: The cohort included 150,642 patients. Of these, 12,985 (9%) were receiving care in nonprofit dialysis facilities. In adjusted models, patients receiving hemodialysis in for-profit facilities had a 15% (95% confidence interval [95% CI], 13% to 18%) higher relative rate of hospitalization compared with those in nonprofit facilities. Among patients receiving peritoneal dialysis, the rate of hospitalization in for-profit versus nonprofit facilities was not significantly different (relative rate, 1.07; 95% CI, 0.97 to 1.17). Patients on hemodialysis receiving care in for-profit dialysis facilities had a 37% (95% CI, 31% to 44%) higher rate of hospitalization for heart failure or volume overload and a 15% (95% CI, 11% to 20%) higher rate of hospitalization for vascular access complications. Conclusions: Hospitalization rates were significantly higher for patients receiving hemodialysis in for-profit compared with nonprofit dialysis facilities.


  • Open Access

    Kidney Function and Prevalent and Incident Frailty

    by Lorien S. Dalrymple, Ronit Katz, Dena E. Rifkin, David Siscovick, Anne B. Newman, Linda F. Fried, Mark J. Sarnak, Michelle C. Odden, Michael G. Shlipak

    Summary: Background and objectives: Kidney disease is associated with physiologic changes that may predispose to frailty. This study sought to investigate whether lower levels of kidney function were associated with prevalent or incident frailty in Cardiovascular Health Study (CHS) participants. Design, setting, participants, & measurements: CHS enrolled community-dwelling adults age ≥65 years between 1989–1990 and 1992–1993. To examine prevalent frailty, included were 4150 participants without stroke, Parkinson disease, prescribed medications for Alzheimer disease or depression, or severely impaired cognition. To examine incident frailty, included were a subset of 3459 participants without baseline frailty or development of exclusion criteria during follow-up. The primary predictor was estimated GFR (eGFR) calculated using serum cystatin C (eGFRcys). Secondary analyses examined eGFR using serum creatinine (eGFRSCr). Outcomes were prevalent frailty and incident frailty at 4 years of follow-up. Frailty was ascertained on the basis of weight loss, exhaustion, weakness, slowness, and low physical activity. Results: The mean age was 75 years and the median eGFRcys was 73 ml/min per 1.73 m2. Among participants with an eGFRcys 2, 24% had prevalent frailty. In multivariable analysis and compared with eGFRcys ≥90 ml/min per 1.73 m2, eGFRcys categories of 45–59 (odds ratio [OR], 1.80; 95% confidence interval [CI], 1.17 to 2.75) and 15–44 (OR, 2.87; 95% CI, 1.72 to 4.77) were associated with higher odds of frailty, whereas 60–75 (OR, 1.14; 95% CI, 0.76 to 1.70) was not. In multivariable analysis, eGFRcys categories of 60–75 (incidence rate ratio [IRR], 1.72; 95% CI, 1.07 to 2.75) and 15–44 (IRR, 2.28; 95% CI, 1.23 to 4.22) were associated with higher incidence of frailty whereas 45–59 (IRR, 1.53; 95% CI, 0.90 to 2.60) was not. Lower levels of eGFRSCr were not associated with higher risk of prevalent or incident frailty. Conclusions: In community-dwelling elders, lower eGFRcys was associated with a higher risk of prevalent and incident frailty whereas lower eGFRSCr was not. These findings highlight the importance of considering non-GFR determinants of kidney function.


  • Longitudinal Measures of Serum Albumin and Prealbumin Concentrations in Incident Dialysis Patients: The Comprehensive Dialysis Study

    by Lorien S. Dalrymple, Kirsten L. Johansen, Glenn M. Chertow, Barbara Grimes, Shuchi Anand, Charles E. McCulloch, George A. Kaysen


  • The Risk of Infection-Related Hospitalization With Decreased Kidney Function

    by Lorien S. Dalrymple, Ronit Katz, Bryan Kestenbaum, Ian H. de Boer, Linda Fried, Mark J. Sarnak, Michael G. Shlipak


  • Open Access

    Risk of Cardiovascular Events after Infection-Related Hospitalizations in Older Patients on Dialysis

    by Lorien S. Dalrymple, Sandra M. Mohammed, Yi Mu, Kirsten L. Johansen, Glenn M. Chertow, Barbara Grimes, George A. Kaysen, Danh V. Nguyen

    Summary Background and objectives Infection and cardiovascular disease are leading causes of hospitalization and death in patients on dialysis. The objective of this study was to determine whether an infection-related hospitalization increased the short-term risk of a cardiovascular event in older patients on dialysis. Design, setting, participants, & measurements With use of the United States Renal Data System, patients aged 65 to 100 years who started dialysis between January 1, 2000, and December 31, 2002, were examined. All hospitalizations were examined from study entry until time of transplant, death, or December 31, 2004. All discharge diagnoses were examined to determine if an infection occurred during hospitalization. Only principal discharge diagnoses were examined to ascertain cardiovascular events of interest. We used the self-controlled case-series method to estimate the relative incidence of a cardiovascular event within 90 days after an infection-related hospitalization as compared with other times not within 90 days of such a hospitalization. Results A total of 16,874 patients had at least one cardiovascular event and were included in the self-controlled case-series analysis. The risk of a cardiovascular event was increased by 25% in the first 30 days after an infection and was overall increased 18% in the 90 days after an infection-related hospitalization relative to control periods. Conclusions The first 90 days, and in particular the first 30 days, after an infection-related hospitalization is a high-risk period for cardiovascular events and may be an important timeframe for cardiovascular risk reduction, monitoring, and intervention in older patients on dialysis.


  • Open Access

    Chronic Kidney Disease and the Risk of End-Stage Renal Disease versus Death

    by Lorien S. Dalrymple, Ronit Katz, Bryan Kestenbaum, Michael G. Shlipak, Mark J. Sarnak, Catherine Stehman-Breen, Stephen Seliger, David Siscovick, Anne B. Newman, Linda Fried

    BACKGROUND Among older adults with chronic kidney disease (CKD), the comparative event rates of end-stage renal disease (ESRD) and cause-specific death are unknown. OBJECTIVE To compare the rates of ESRD, cardiovascular and non-cardiovascular death and examine risk factors for ESRD and all-cause mortality in Cardiovascular Health Study (CHS) participants. Design The CHS is a longitudinal cohort study of community-dwelling adults aged 65 years and older. PARTICIPANTS 1,268 participants with an estimated glomerular filtration rate (eGFR) < 60 ml/min per 1.73 m2 were followed until the time of first event (ESRD, cardiovascular or non-cardiovascular death) or until March 31, 2003. MAIN MEASURES The outcomes were ESRD, cardiovascular- and non-cardiovascular death. Rates of each event were calculated, and a Cox Proportional Hazards Model with a competing risk framework was used to examine risk factors for ESRD as compared with death. Predictors included age, gender, race, BMI, hypertension, diabetes, cardiovascular disease, heart failure, tobacco use, eGFR, and total cholesterol. KEY RESULTS During 9.7 years of follow-up, 5% of the cohort progressed to ESRD, and 61% of the cohort died. The rate (per 100 person-years) was 0.5 for ESRD and 6.8 for all-cause mortality (3.0 for cardiovascular and 3.8 for non-cardiovascular mortality). In the competing risk framework, lower eGFR, male gender, African-American race, and higher BMI were associated with an increased risk of ESRD. CONCLUSIONS Older adults with CKD are 13-fold more likely to die from any cause than progress to ESRD and are 6-fold more likely to die from cardiovascular causes than develop ESRD.


  • Infection-Related Hospitalizations in Older Patients With ESRD

    by Lorien S. Dalrymple, Kirsten L. Johansen, Glenn M. Chertow, Su-Chun Cheng, Barbara Grimes, Ellen B. Gold, George A. Kaysen


  • Open Access

    Epidemiology of Acute Infections among Patients with Chronic Kidney Disease

    by Lorien S. Dalrymple, Alan S. Go

    The objectives of this review were (1) to review recent literature on the rates, risk factors, and outcomes of infections in patients who had chronic kidney disease (CKD) and did or did not require renal replacement therapy; (2) to review literature on the efficacy and use of selected vaccines for patients with CKD; and (3) to outline a research framework for examining key issues regarding infections in patients with CKD. Infection-related hospitalizations contribute substantially to excess morbidity and mortality in patients with ESRD, and infection is the second leading cause of death in this population. Patients who have CKD and do not require renal replacement therapy seem to be at higher risk for infection compared with patients without CKD; however, data about patients who have CKD and do not require dialysis therapy are very limited. Numerous factors potentially predispose patients with CKD to infection: advanced age, presence of coexisting illnesses, vaccine hyporesponsiveness, immunosuppressive therapy, uremia, dialysis access, and the dialysis procedure. Targeted vaccination seems to have variable efficacy in the setting of CKD and is generally underused in this population. In conclusion, infection is a primary issue when caring for patients who receive maintenance dialysis. Very limited data exist about the rates, risk factors, and outcomes of infection in patients who have CKD and do not require dialysis. Future research is needed to delineate accurately the epidemiology of infections in these populations and to develop effective preventive strategies across the spectrum of CKD severity.


  • Open Access

    The Effect of Lipoproteins on the Development and Progression of Renal Disease

    by Lorien S. Dalrymple, George A. Kaysen

    The field of research examining how lipoproteins may contribute to the development and/or progression of renal disease has rapidly expanded over the last 25 years. In animal models, lipoproteins and lipids have been associated with both the initiation and progression of renal disease. Numerous potential mechanisms of lipoprotein-induced renal injury have been identified by utilizing animal models and tissue-culture experiments. However, with the exception of rare genetic mutations, the association between lipoproteins and human renal disease is less clear. In humans, the evidence that lipid-lowering therapy delays renal progression is limited. The purpose of this paper is to review the current literature on lipoprotein abnormalities and the development or progression of renal disease.